Delivery Order SPE2DB25D7068-SPE2DB25FTXYM
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $5,987.47 to AmerisourceBergen Drug Corp for the supply of Dupixent 300 mg/2 ml pen injectors on August 5, 2025, with an ultimate completion date of August 6, 2025. This competitive award, issued under firm fixed pricing, represents a child contract to AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. The place of...
- The Defense Logistics Agency awarded a $29,850.86 delivery order to AmerisourceBergen Drug Corp on July 25, 2025, for the supply of Dupixent 300 mg/2 ml pen injectors. The contract, designated as a firm fixed price delivery order with an ultimate completion date of July 28, 2025, will be performed at the vendor's corporate office location in Conshohocken, Pennsylvania. This award was made through open competition with no set-aside designation, reflecting AmerisourceBergen's established...
- The Defense Logistics Agency awarded a delivery order valued at $20,876.59 to AmerisourceBergen Drug Corp for the supply of Dupixent 300 mg/2 ml pen injectors on August 14, 2025, with an ultimate completion date of August 15, 2025. This firm fixed-price delivery order, which carries no set-aside designation, represents a competitively awarded contract supporting the federal government's pharmaceutical supply chain. The contract will be performed at AmerisourceBergen's corporate office location...
- The Defense Logistics Agency Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on September 9, 2025, for the supply of Dupixent 300 mg/2 ml pen injections with a ceiling value of $391,967.30. This competitively awarded, firm fixed-price delivery order is scheduled for completion by September 10, 2025, and will be fulfilled from the vendor's facility in Conshohocken, Pennsylvania. The contract represents a child order under AmerisourceBergen's broader pharmaceutical...
- The Defense Logistics Agency awarded a $12,949.95 delivery order to AmerisourceBergen Drug Corp on July 18, 2025, for the supply of Dupixent 300 mg/2 mL pen injectors (2 mL units). This is a firm fixed-price delivery order with an ultimate completion date of July 21, 2025, and represents a non-set-aside award. The products will be delivered to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite...
- On August 5, 2025, the Defense Logistics Agency awarded a delivery order valued at $48,364.69 to AmerisourceBergen Drug Corp for the supply of Dupixent 300 mg/2 ml pen injections. This firm fixed-price delivery order, which is not set-aside designated, represents a competitive award under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 and extending through December 2026. The products will be delivered to AmerisourceBergen's...
- The Defense Logistics Agency awarded a $9,133.25 delivery order to AmerisourceBergen Drug Corp on July 28, 2025, for the supply of Dupixent 300 mg/2 ml pen injections. This is a firm fixed price delivery order with an ultimate completion date of July 29, 2025, representing a short-duration pharmaceutical supply contract. The award carries no set-aside designation, indicating it was competitively awarded through open procurement processes. AmerisourceBergen's corporate office in Conshohocken,...
- The Defense Logistics Agency awarded a delivery order valued at $36,944.08 to AmerisourceBergen Drug Corp for Dupixent 300 mg/2 ml pen injectors on August 14, 2025, with completion scheduled for August 15, 2025. This firm fixed price, competitively awarded delivery order represents a direct fulfillment under the company's existing pharmaceutical supply agreement with DLA. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, serves as a critical pharmaceutical distributor for...
- The Department of Defense's Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on September 9, 2025, for the supply of Dupixent 300 mg/2 ml pen injections with a ceiling value of $59,030.74. This is a firm fixed-price delivery order with no set-aside designation, indicating the award was made through open competition. The order is scheduled for completion by September 10, 2025, and will be fulfilled at AmerisourceBergen's corporate office location in Conshohocken,...
- The Defense Logistics Agency awarded a $7,353.02 delivery order to AmerisourceBergen Drug Corp on July 21, 2025, for the supply of Dupixent 300 mg/2 mL pen injectors. This non-set-aside, competitively awarded contract carries a firm fixed price and is scheduled for completion by July 22, 2025, with the place of performance located in Conshohocken, Pennsylvania. The delivery order represents a discrete transaction under AmerisourceBergen's larger pharmaceutical supply relationship with the...
- SPE2DB25D7068Indefinite Delivery Contract
- SPE2DB25D7068-SPE2DB25FTXYMDelivery Order
The Defense Logistics Agency awarded a $20,513.52 delivery order to AmerisourceBergen Drug Corp on September 12, 2025, for the supply of Dupixent 300 mg/2 mL pen injectors. This competitively awarded, firm fixed price contract carries an ultimate completion date of September 15, 2025, and represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. The product will be delivered to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is part of AmerisourceBergen's comprehensive pharmaceutical supply agreement with the Defense Logistics Agency, which enables the company to furnish a broad portfolio of medications, vaccines, medical devices, and specialized healthcare commodities to support military and federal healthcare systems worldwide. As a major pharmaceutical distributor and critical vendor for federal medical procurement, AmerisourceBergen maintains an extensive track record of fulfilling DLA requirements across multiple therapeutic domains. The award carries no set-aside designation, demonstrating the company's capability to compete successfully in open federal procurement processes for pharmaceutical products supporting defense health operations.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $20.5k | 9/12/25 |